2026 BD opportunity scan for Inimmune Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Inibio, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Inhibikase Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rational

2026 BD opportunity scan for Incyte Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Incannex Healthcare, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Immunomic Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale

2026 BD opportunity scan for ImmuneOnco Biopharmaceuticals (Shanghai), Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and

2026 BD opportunity scan for Idorsia Pharmaceuticals Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale

2026 BD opportunity scan for iCell Gene Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rational

2026 BD opportunity scan for Hyperway Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rati

2026 BD opportunity scan for HUTCHMED (China) Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Hunan Zhengtai Jinhu Pharmaceutical Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and ou